Previous close | 1.7900 |
Open | 1.9700 |
Bid | 1.9200 |
Ask | 2.0100 |
Strike | 62.50 |
Expiry date | 2024-08-16 |
Day's range | 1.9700 - 1.9700 |
Contract range | N/A |
Volume | |
Open interest | 2.37k |
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
Unraveling the Financial Dynamics and Strategic Directions of Gilead Sciences Inc (GILD)
FOSTER CITY, Calif. & SANTA MONICA, Calif., May 07, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing commitment to developing differentiated approaches to transform how cancer is treated and span solid tumors and blood cancers, including lung, breast, gastrointestinal, colorectal, leukemia and lymphoma.